Background Activating FGFR2 mutations are found in 10-16% of primary endometrial cancers and provide an opportunity for targeted therapy. We assessed the safety and activity of dovitinib, a potent tyrosine-kinase inhibitor of fi broblast growth factor receptors, VEGF receptors, PDGFR-β, and c-KIT, as second-line therapy both in patients with FGFR2-mutated (FGFR2
Introduction
Endometrial cancer is the most common gynaecological malignancy in women in Europe and the USA. 1, 2 Although most cases are detected at an early stage and cured with surgery alone or with adjuvant therapy, women with advanced or metastatic endometrial cancer have a poor prognosis, and few treatment options are available. Hormonal drugs or chemotherapies have little activity after fi rst-line treatment, with median progression-free survival generally shorter than 3 months and median overall survival shorter than 12 months. [3] [4] [5] [6] [7] Thus, new treatment approaches are urgently needed.
Despite recent advances in the molecular characterisation of endometrial cancer, treatment strategies do not include target-based therapies. 8, 9 Fibroblast growth factor receptor 2 (FGFR2) could be a novel molecular target. 10 Investigators have identifi ed activating mutations in 10-16% of primary endometrial cancers, and these are more frequent in cancers of endometrioid histological subtype compared with serous or clear-cell subtypes. [8] [9] [10] Gain-of-function mutations in the kinase domain (ie, N549K substitution) lead to ligand-independent activation of the receptor, whereas mutations in the extracellular ligand-binding domain (ie, S252W or P253R substitution) increase the affi nity for fi broblast growth factors (FGFs). 8, [10] [11] [12] Both types of mutations have been shown to be potentially oncogenic in endometrial cancer cell lines. 11 Importantly, FGFR2 mutations are of independent prognostic relevance in early-stage endometrioid endometrial cancer, suggesting a role as oncogenic drivers. 12 Dovitinib (TKI258) is a reversible ATP-competitive receptor tyrosine-kinase inhibitor that targets FGFR1, FGFR2, FGFR3, VEGFR1, VEGFR2, VEGFR3, PDGFR-β, c-KIT, and other kinases. 13 Dovitinib selectively inhibited the growth of endometrial cancer cell lines with FGFR2 mutations by blocking FGFR2 signalling, inducing cellcycle arrest, and increasing apoptosis. 14 In mice, dovitinib showed dose-dependent growth inhibition of both FGFR2-mutated (FGFR2 mut ) and FGFR2-nonmutated (FGFR2 non-mut ) endometrial xeno grafts. 14, 15 These preclinical data suggest that dovitinib might act not only via direct anti-tumour eff ects (inhibition of FGFR2) but also through inhibition of the formation and maintenance of tumour vasculature (inhibition of VEGFR1, VEGFR2, VEGFR3, FGFR1, FGFR2, FGFR3, and PDGFR-β), 15 thereby providing rationale for evaluation of dovitinib in both FGFR2 mut and FGFR2 non-mut patient populations. We did a clinical study to evaluate the effi cacy and safety of dovitinib as second-line therapy in patients with FGFR2 mut or FGFR2 non-mut advanced or metastatic endometrial cancer. Since FGFR2 mutations are less frequent in endometrial cancer, it was necessary to accrue FGFR2 mut and FGFR2 non-mut groups separately to ensure an adequate number of evaluable patients.
Methods

Study design and participants
For this non-randomised, multicentre, open-label, twogroup, two-stage, phase 2 trial, we enrolled women aged 18 years or older with advanced or metastatic endometrial cancer with progressive disease (per Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1) after fi rstline antineoplastic treatment (including at least one cytotoxic drug). We did not consider neoadjuvant and adjuvant treatments to be a previous line of treatment, unless the recurrence occurred at or within 6 months since the last administration of neoadjuvant or adjuvant chemotherapy. We did not consider hormonal therapy in any setting to be a line of treatment. Eligible histological disease types included endometrioid, serous, clear-cell, mucinous, adeno squamous, and mixed types. Key additional eligibility criteria included tissue specimen for FGFR2 assessment, Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, and at least one measurable lesion. Key exclusion criteria included more than one previous line of chemotherapy for advanced or metastatic disease, previous treatment with an FGFR inhibitor, known brain metastases, and impaired cardiac function or clinically signifi cant cardiac disease. A full list is provided in the appendix.
The protocol and amendments were reviewed by each centre's independent ethics committee or institutional review board. All patients provided written informed consent. The trial was done in accordance with the ICH Harmonised Tripartite Guidelines for Good Clinical Practice, with applicable local regulations, and with the ethical principles of the Declaration of Helsinki.
Procedures
Patients were treated with 500 mg dovitinib (Novartis Pharmaceuticals, East Hanover, NJ, USA), orally on a 5-days-on and 2-days-off schedule until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment due to any other reason. The dose and schedule for single-agent dovitinib were based on pharmacokinetic modelling and data from a phase 1 trial in patients with renal-cell carcinoma,
Research in context
Evidence before this study In February, 2015, we searched PubMed for papers with the search terms "endometrial" and "fi broblast growth factor receptor" with no limits on publication date or language. Before we started our study, retrospective analyses of endometrial tumours had identifi ed activating mutations in FGFR2. These mutations had been targeted with fi broblast growth factor receptor (FGFR) inhibitors in preclinical, but not clinical, reports.
Added value of this study
Our search identifi ed two clinical trials with inhibitors of FGFRs, nintedanib and brivanib, that were published after the start of our study. However, investigators for these trials did not prospectively group patients on the basis of FGFR2 mutations and only nintedanib has an IC 50 for FGFR2 that is similar to dovitinib (37 nmol/L vs 40 nmol/L), limiting comparison of these results. Therefore, to our knowledge, our study is the largest trial with an FGFR inhibitor and is the fi rst of its kind to prospectively group patients with endometrial cancer on the basis of FGFR2 status.
Implications of all the available evidence
Although there was insuffi cient activity to proceed to stage two, dovitinib showed some activity in FGFR2 mut and FGFR2 non-mut patients. Therefore, FGFR-pathway inhibition remains promising. More potent and selective FGFR inhibitors could improve clinical activity and reduce toxicity in this population. Additional studies are necessary before implementation in the clinic.
See Online for appendix which showed steady state was achieved by the second week. 16, 17 Investigators could manage dovitinib-related toxicities with dose interruptions (up to 21 days) or dose reductions (400 mg then 300 mg per day on the same schedule). Dose re-escalation was not permitted.
We classifi ed women into two groups on the basis of FGFR2 mutation status (FGFR2 mut or FGFR2 non-mut ). We established FGFR2 status by Sanger sequencing (on archival tumour blocks or fresh fi xed tumour biopsies) of the fi ve main hotspot mutation sites reported for endometrial cancer within exons 7, 8, 9, 11, and 13. 18 Tumour assessments were done with CT or MRI every 6 weeks until disease progression, with an additional assessment for complete response or partial response within 4 weeks after the criteria for response were fi rst met. 19 Activity was assessed locally and reviewed centrally for all enrolled patients. Safety was assessed in all patients who received at least one dose of dovitinib and included monitoring of adverse events; haematology; blood chemistry; urinalysis; and regular vital signs, physical examination, performance status, electro cardiograph, and cardiac imaging assessments. Urinalysis, blood chemistry, and haematology were assessed on days 1, 33, and 43 after the start of treatment and every 21 days thereafter, with blood chemistry and haematology also being assessed on day 12. Adverse events were assessed according to Common Terminology Criteria for Adverse Events version 4.03 throughout the study and 30 days after the last dose of study treatment (on treatment). Blood samples for dovitinib trough concentrations were collected predose on day 5 of weeks 2, 4, and 6, and on day 1 every 12 weeks beginning week 13.
Archival tumour samples remaining from FGFR2 screening were tested for mutations and copy number variations with the FoundationOne targeted next-genera- 
Outcomes
The primary endpoint was the proportion of patients in each group who were progression free (by investigator assessment with RECIST version 1.1) at 18 weeks in the whole population of each group. 19 Published criteria consider the progression-free survival rate at a predefi ned timepoint an appropriate endpoint to identify a signal of biological activity in a phase 2 setting, and this early signal would inform further clinical development. 19 The key secondary endpoint was the proportion of patients who achieved an overall response (defi ned as a complete response or partial response). Additional secondary endpoints were the proportion of patients who achieved disease control (defi ned as overall response plus stable disease), duration of response, progression-free survival, overall survival, safety, tolerability, dovitinib trough concentrations, and pharmacodynamic changes from baseline.
Statistical analysis
We used a two-stage design for the FGFR2 mut group and the FGFR2 non-mut group to inform a go or no-go decision for a larger, randomised phase 3 trial. At least 20 patients were to be enrolled per stage. Stage two could proceed if at least eight of the fi rst 20 treated patients (40%) with measurable disease at baseline met the primary endpoint. If, at the end of stage 2, 50% or more patients were progression-free at 18 months (and there was ≥0·95 probability that the rate was >20%), then evidence of a dovitinib treatment eff ect was to be concluded because it would show a 50% or greater improvement in progression-free survival compared with historical controls of hormonal drugs and chemotherapies after fi rst-line treatment, in which patients achieved progression-free survival of less than 3 months and [3] [4] [5] [6] [7] Because of the small sample size, which was based on the statistical assumptions described above, we planned no multivariate analysis to model the FGFR mutation status and survival adjusting for baseline clinical parameters.
We used descriptive statistics to summarise the fi ndings in both groups, including the primary endpoint of proportion of patients progression-free at 18-weeks. A 95% Clopper-Pearson (exact) CI was also calculated for primary endpoint. We used the Kaplan-Meier method to analyse progression-free survival and overall survival. Progression-free survival was defi ned as the time from the start date of study drug to the date of the fi rst radiologically documented disease progression or death due to any cause. If a patient had not progressed or died at the date of analysis cutoff date or had received any further anticancer therapy, data was censored at the date of the last adequate tumour evaluation before the cutoff date or before the start of the new anticancer therapy date, whichever was earlier. Overall survival was defi ned as the time from the start date of the study drug to the date of death due to any cause. If a patient was not known to have died, then overall survival was censored at the last contact date. Data were analysed with SAS version 9.4.
The trial is registered with ClinicalTrials.gov, number NCT01379534.
Role of the funding source
The funder and the study steering committee participated in study design and data collection, analysis, and interpretation. Primary data were accessible to all authors. GEK had the fi nal responsibility for the decision to submit for publication.
Results
283 patients from 46 sites in seven countries (appendix) consented to molecular prescreening (fi gure 1). Of the 248 patients with FGFR2 mutational status results, 27 (11%) had mutations in the gene, most commonly S252W and N549K (fi gure 1). The remaining 221 patients were FGFR2
non-mut (including 166 patients who were identifi ed after enrolment to the group was closed).
Between non-mut group were progression-free at 18 weeks (appendix). In the planned interim analysis, seven mut group were progression-free at 18 weeks. On the basis of the predefi ned criteria of a threshold of 40% rate, neither group of patients were continued to stage two of the study.
The median follow-up for progression-free survival in all patients was 2·7 months (IQR 1·3-5·5). The median progression-free survival by local investigator assessment was 4·1 months (95% CI 2·6-5·5) in the FGFR2 mut group and 2·7 months (1·4-6·8) in the FGFR2 non-mut group (fi gure 2). The probability of being progression free at 18 weeks based on a Kaplan-Meier analysis was 47·8% (95% CI 24·8-67·7) in the FGFR2 mut group and 37·9% (19·7-56·0) in the FGFR2 non-mut group (fi gure 2). The median follow-up for overall survival in all patients was 7·8 months (IQR 4·6-13·2) non-mut ) patients had at least one dose delay or interruption. The geometric mean values and range of dovitinib trough concentrations were similar between the two groups. Consistent with the 5-days-on and 2-days-off schedule, trough concentrations on day 5 were generally greater than those on day 1 (appendix).
Adverse events were similar between the groups and most commonly gastrointestinal (table 3) . The most common adverse events suspected to be related to study No patient had a QTcF interval longer than 480 ms, and none of the 52 patients with baseline electrocardiograms had an increase from baseline of longer than 60 ms. Additionally, none of the patients who had both pretreatment and post-treatment echocardiograms (n=19) or multiple-gated acquisition scans (n=5) had a 20% or greater decrease from baseline cardiac ejection fraction.
Of the fi ve on-treatment deaths, four patients died due to endometrial cancer and one died due to an ad verse event suspected to be treatment-related. In this FGFR2 non-mut patient, the primary reason for death was cardiac arrest with contributing reason of grade 4 pulmonary embolism, suspected to be study drug related, which occured 4 days previously.
48 (91%) patients enrolled in the study had tissue samples available for exploratory biomarker analysis, of which 44 samples were available for next-generation sequencing for somatic gene alterations. Beyond the known FGFR2 mutations, we did not identify molecular abnormalities in FGF receptors or ligands (data not shown).
Discussion
Second-line dovitinib showed some clinical activity in FGFR2 mut and FGFR2 non-mut advanced or metastatic endometrial cancer. To our knowledge, this is the fi rst report showing activity of a single-agent tyrosine-kinase inhibitor in patients with recurrent advanced or metastatic FGFR2 mut endometrial cancer. Indeed, about a third of patients receiving second-line dovitinib in the FGFR2 mut group were progression-free at 18 weeks. Although this group did not continue to stage two based on the predefi ned 40% threshold, the proportion of patients who achieved clinical benefi t was 64%, progression-free survival was 4 months, and the median overall survival was 20 months. Given the poor effi cacy of alternative treatment options for recurrent advanced or metastatic endometrial cancer that has progressed after fi rst-line chemotherapy, the clinical activity for dovitinib in the FGFR2 mut group seems to be clinically meaningful.
Although the frequency of FGFR2 mutations in our cohort is consistent with that of earlier reports (11-16%), previous studies included only patients with primary endometrial cancer and focused on endometrioid endometrial cancer and so might have had more mutations. 8, [10] [11] [12] The mutation frequency in our study of advanced endometrial cancer was at the low end of the range, which could refl ect the high proportion of tumours with serous and clear-cell histology fi ndings, which are usually not FGFR2 mut . S252W, which was the most commonly identifi ed mutation in the FGFR2 mut group, enables the receptor to bind FGF2 and FGF9, leading to autocrine activation of FGFR2. 10 Mutations in the kinase domain were identifi ed in six tumours, and fi ve additional mutations were noted in the trans membrane domain or 14 potentially showing dovitinib's anti -angiogenic activity. 15 In our study, around 29% of individuals with tumours that were FGFR2 non-mut were progression-free at 18 weeks and the probability of being progression free at 18 weeks based on KaplanMeier analysis was 37·9%. Although, the proportion of patients achieving a clinical benefi t in the FGFR2 non-mut group (52%) could be seen as promising (especially since high-grade tumours were included), responses were short lasting. Nonetheless, the observed clinical activity is similar to what has been reported for hormonal drugs or chemotherapies after fi rst-line treatment of advanced or metastatic endometrial cancer. [3] [4] [5] [6] [7] Since this activity was similar to that seen in the FGFR2 mut group, testing for FGFR2 mutations would not be a useful enrichment strategy if dovitinib was to be used clinically. The shorter overall survival in the FGFR2 non-mut group (compared with the FGFR2 mut group) could be attributed to the more adverse prognostic tumour characteristics in the former. Although these data need to be interpreted with caution because of the small number of patients in each group and the overlapping confi dence intervals, they are of particular interest because next-generation sequencing did not identify molecular abnormalities of the other FGF receptors or ligands. Thus, activity in patients with FGFR2
non-mut tumours might be refl ective of the antiangiogenic eff ects of dovitinib.
Bevacizumab inhibition of the VEGF pathway has shown clinical activity in endometrial cancer. 21 However, anti-angiogenic escape can occur via activation of several pathways, including those involving plateletderived growth factor and FGF. 22 Although sunitinib, a VEGFR1, VEGFR2, VEGFR3, and PDGFR-β 23 inhibitor, also demonstrated activity in this population, the ability of dovitinib to potently inhibit FGFR1, FGFR2, and FGFR3 might provide broader protection against antiangiogenic escape.
Unfortunately, our study was not able to establish whether the eff ects seen in the FGFR2 mut group were due to FGFR2 inhibition only or also due to the antiangiogenic eff ects from FGFR1, FGFR2, FGFR3, VEGFR1, VEGFR2, VEGFR3, and PDGFR-β as seen in the FGFR2 non-mut group. A clinical trial with a more potent and selective FGF receptor inhibitor such as Data are n (%). All patients (n=53). Shows adverse events suspected to be related to study drug, and includes grade 1 or 2 events recorded in more than 10% of patients, and any grade 3 or 4 events. Thus additional studies are needed with more specifi c FGFR2 inhibitors before FGFR2 testing could be used clinically. Another limitation is that more than a third of the study patients in both groups had drug exposure of less than 6 weeks and stopped the study drug before the fi rst assessment of treatment response. The trial staff s' lack of experience in the management of mild or moderate class-specifi c treatment-related side-eff ects early in the trial might have contributed to this high rate of patient discontinuation. Although cross-trial comparisons must be made with caution, and despite the described limitations, in comparison to previous studies we believe our study is the most robust analysis of an inhibitor of FGF receptors in patients with FGFR2 mut endometrial cancer. Investi gators have previously reported results of a phase 2 study of brivanib, an inhibitor of VEGF receptor and FGF receptor, in patients with recurrent or persistent endometrial cancer after one or two cytotoxic regimens. 26 19% of these patients receiving brivanib achieved an overall response, and they had a progression-free survival rate at 6 months of 30·2% (90% CI 18·9-43·9). 26 However, the eff ect of FGFR2 inhibition in that study is not clear because only three patients had FGFR2 mutations. 13, 27 In another phase 2 study of single-agent nintedanib (an inhibitor of VEGF, platelet-derived growth factor, and FGF receptors that has a similar half maximal inhibitory concentration against FGFR2 as has dovitinib) 28 9·4% of patients with recurrent or persistent, previously treated endometrial cancer achieved an overall response, and the progression-free survival rate at 6 months was 21·9%. 29 However, tissue specimens were not collected and FGFR2 status of patients was not known.
The safety results in this study are consistent with the known safety profi le of dovitinib. The most common adverse events were gastrointestinal (diarrhoea, vomiting, and nausea), with most events mild to moderate (grade 1 or 2) and manageable with dose adjustments or interruptions. The rate of thromboembolic events was higher in this study compared with that reported in other dovitinib studies. 30, 31 However, venous thromboembolism is thought to be a comorbidity in women with gynaecological cancers, especially in patients with advanced or metastatic tumours. 32 In our study, second-line dovitinib in FGFR2 mut advanced or metastatic endometrial cancer had singleagent activity, but did not meet the endpoint for stage two of the trial. These data should be con sidered exploratory and additional studies are needed. Importantly, our fi ndings emphasise the need for further study of drugs that selectively target FGFR2 in patients with endometrial cancer, but they also underscore the call to further study multikinase inhibitors targeting both FGF and VEGF pathways in FGFR2 non-mut advanced or metastatic endometrial cancer.
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